Neuroblastoma Drugs Market To Achieve Significant Growth In The Near Future With Demand, Size, Trend, Segmentation, Growth Opportunities -2023

MFR Research Report Offering Encompasses Different Strategies, Such As Mergers & Acquisitions, Partnerships & Collaborations, Business Expansions, And Product Developments, Adopted By Major Players

PUNE, India - July 11, 2019 /MarketersMedia/ —

Market Highlights

The global neuroblastoma is anticipated to hold a market value of 2.60 billion in 2017 and is expected to grow at a CAGR of 3.7% during the forecast period. Neuroblastoma is a childhood cancer most commonly occurs in children below the age of 5 years.

The neuroblast may cause due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation. The increasing cases of childhood cancer, rising research on neuroblastoma treatment and increasing spending on cancer treatment is expected to drive market growth over the forecast period. According to the American Society of Clinical Oncology (ASCO) April 2018 publication, every year, more than 700 children get diagnosed with neuroblastoma in the US and it is also indicated that neuroblastoma is the most common cancer in children younger than 1 year. It is more commonly found in boys compare to girls. The increasing cases of childhood cancer boost market growth during the forecast period.

Despite the drivers, shortage of trained healthcare specialists and the high cost of this therapy can restrain the market growth over the assessment period.

Request to Get free  the Sample Pages at - https://www.marketresearchfuture.com/sample_request/6555
Key Players

Some of the prominent players in the global neuroblastoma market are United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others.

Segmentation

The global neuroblastoma market has been segmented into diagnostics, treatment, and end user.

The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.

The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment.

On the basis of end user, the global neuroblastoma market has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.

Regional Analysis

Asia-Pacific is expected to be the fastest growing market owing to the increasing children cancer base and increasing developments in the healthcare segment.

Geographically, the Americas is expected to dominate the global neuroblastoma market owing to the presence of well-developed healthcare sector, rising prevalence of infant cancer cases, and growing expenditure for the healthcare sector. Europe is expected to hold the second largest position in the global neuroblastoma market owing to the growing number of child healthcare centers for cancer treatment and raising awareness about the treatment for neuroblastoma.  According to the Cancer Research UK May 2018 publication, around 100 infants are detected with neuroblastoma every year in the UK. This provides favorable backgrounds for the neuroblastoma market to grow.

According to the Neuroblastoma Australia organization October 2018 article, every year approximately 40 cases of neuroblastoma are indicated in Australia due to some unknown genetic problems which will support the market growth.

 Furthermore, the Middle Eastern and African region is expected to account for the least market share in the global market.

Access Report @ https://www.marketresearchfuture.com/reports/neuroblastoma-market-6555
About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

 MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Info:
Name: Abhishek Sawant
Email: Send Email
Organization: Market Research Future
Address: Contact:, , Market Research Future, , Office No. 528, Amanora Chambers, , Magarpatta Road, Hadapsar,, , Pune - 411028, , Maharashtra, India, , +1 646 845 9312, , Email: sales@marketresearchfuture.com
Phone: 646845931
Website: https://www.marketresearchfuture.com

Source URL: https://marketersmedia.com/neuroblastoma-drugs-market-to-achieve-significant-growth-in-the-near-future-with-demand-size-trend-segmentation-growth-opportunities-2023/88895456

Source: MarketersMedia

Release ID: 88895456

Latest News

Asian stocks gain after US, China announce truce on tariffs

Oct 14, 2019

BEIJING — Asian stock markets have risen after Washington and Beijing announced a truce on tariff hikes in a trade war. Benchmarks in Shanghai, Hong Kong and Seoul advanced. Japanese markets were closed for a holiday. President Donald Trump agreed Friday to put off planned tariff hikes this week on Chinese goods in a fight over Beijing's trade surplus and technology plans. In exchange, he said China would buy American farm goods. But the two sides reported no progress on basic disputes that sparked the 15-month-old fight that threatens global economic growth. Friday's truce "has simply temporarily halted the escalation...

Japan looks for missing after typhoon, warns of mudslides

Oct 14, 2019

TOKYO — Rescue crews in Japan dug through mudslides and searched near swollen rivers Monday as they looked for those missing from a typhoon that left as many as 36 dead and caused serious damage in central and northern Japan. Typhoon Hagibis unleashed torrents of rain and strong winds Saturday that left thousands of homes on Japan's main island flooded, damaged or without power. Authorities warned more mudslides were possible with rain forecast for the affected area during the day Monday. Kyodo News service, assembling information from a wide network, counted 36 deaths caused by the typhoon with 16 people...

Impeachment dominates, but much other work awaits Congress

Oct 14, 2019

WASHINGTON — Impeachment may have leapfrogged to the top of the national agenda, but members of Congress still have their day jobs as legislators, and they're returning to work this week with mixed hopes of success. It's a difficult-to-predict time when it comes to possible deals between President Donald Trump and House Speaker Nancy Pelosi, who's kicked off the impeachment inquiry. An important trade agreement has a pulse. An effort to deal with prescription drug prices seems stuck. Divided government has produced scant results thus far, except for a small-scale budget deal that lawmakers are struggling to put in place....

The Latest: Germany to curtail arms exports to Turkey

Oct 14, 2019

AKCAKALE, Turkey — The Latest on Turkey's military offensive into northeastern Syria against Syrian Kurdish fighters (all times local): 10:05 p.m. Germany's foreign minister has announced that the country will curtail its arms exports to Turkey, which has started a military offensive into northeastern Syria against Syrian Kurdish fighters. Heiko Maas on Saturday told weekly Bild am Sonntag that, "against the background of the Turkish military offensive in northeastern Syria, the government will not issue any new permissions for any weapons that can be used by Turkey in Syria." Maas' remarks came as thousands of Kurdish immigrants rallied against the...

Xi becomes 1st Chinese president in 2 decades to visit Nepal

Oct 14, 2019

KATHMANDU, Nepal — Xi Jinping on Saturday became the first Chinese president in more than two decades to visit Nepal, where he is expected to sign agreements on several infrastructure projects. Xi arrived Saturday from India, where he met with Indian Prime Minister Narendra Modi. Nepal is expected to tread cautiously while building relations with big neighbors India and China. India has extensive influence on Nepal's economy and politics, while China and Nepal share a border covered with high mountain peaks. Jiang Zemin had been the last Chinese president to visit Nepal, making the trip in 1996, but other Chinese...

Search

Deck Biz is an intelligent platform providing international and regional business news updates. You won’t get these insights elsewhere other than Deck Biz.

Contact us: sales@deckbiz.com